MedTrace Logo

Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders

NCT01832597 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 109

Last updated 2013-04-16

No results posted yet for this study

Summary

The purpose of this study is collect and evaluate the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.

Conditions

Sponsors & Collaborators

  • Gruppo Italiano Studio Linfomi

    lead OTHER

Principal Investigators

  • Stefano Luminari, MD · Gruppi Italiano Studi Linfomi

  • Emilio Iannitto, MD · Gruppo Italiano Studio Linfomi

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2010-12-31
Completion
2011-01-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01832597 on ClinicalTrials.gov